praulent
Sanofi and Regeneron meet endpoint in Phase III Praluent study
March 23, 2016Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial
Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
